Brain metastases (BMs) are a common and fatal consequence in patients with advanced malignancies.
Mutations happening in the epidermal growth factor receptor (EGFR) are associated with an elevated risk BMs, occurring in approximately 20-40% of patients.
This study evaluates the safety and efficacy of different radiotherapy (RT) modalities in patients with EGFR-mutant lung cancer brain metastases.
